In 2020, intravitreal brolucizumab became available for the treatment of wet AMD (3); however, early reports (4) suggest a higher incidence of adverse events with this drug than with other intravitreal anti-VEGF injections, including intraocular inflammation, retinal artery occlusion, and vasculitis.